AU2510592A

AU2510592A - Homeopathic compositions for the treatment of viral and metabolic diseases

Info

Publication number: AU2510592A
Application number: AU25105/92A
Authority: AU
Inventors: Marie-Christine Etienne
Original assignee: Individual
Current assignee: Individual
Priority date: 1991-08-29
Filing date: 1992-08-21
Publication date: 1994-03-15
Also published as: EP0655928A1; EP0655928B1; DE69223811T2; DE69223811D1

Description

HOMEOPATHIC COMPOSITIONS FOR THE TREATMENT OF VIRAL AND METABOLIC DISEASES The present invention relates to a novel thera 05 peutic application of homeopathic remedies for the treatment of metabolic diseases and viral diseases with compounds which may or may not be known in the state of the art and which are characterized by the general formula RxCH. 10 The metabolic diseases to which the invention relates are diseases characterized by the intracellular accumulation or intracellular deficit of a chemical substance of simple or complex formula, which can vary from case to case and is designated here by R. 15 In fact, R acts on the pericellular transport systems with respect to itself, which systems have broken down and to which it restores correct function. These diseases are frequently referred to as genetic in the prior art, which acknowledges its inability to cure 20 them. In the case of viral diseases, R is a viral particle which can vary from the whole virus to a minimal fragment, and R causes the elimination of the viral particle from the cell. 25 Homeopathic remedies are known to be defined by a dilution and a dynamization. In the prior art, the use of homeopathic remedies is based on the law of similars, the principle of similars, the principle of infinitesimality, and provings. 30 - The law of similars states the following: "Any pro duct which, when administered at a high dose, produces certain disorders in the healthy becomes, at a very low dose, i.e. after homeopathic dilution, the remedy which is capable of curing these same disorders in the 35 diseased". The law of similars therefore consists in -2 giving the patient an infinitesimal dose, i.e. a homeopathic dilution, of the substance which, when administered to a healthy subject, causes symptoms similar to those of the patient. 05 - Tf similars states the following: "Every diseased organism has a symptom complex which represents the disease. Every substance develops in the organism symptoms which are peculiar thereto and which depend on the substance 10 and the receptivity of the sensitive organism. The cure, objectified by the disappearance of the morbid symptoms, can be obtained by prescribing a substance whose effects are similar to those of the observed 15 The therapeutic use of homeopathic remedies in the prior art therefore consists in causing a series of symptoms to disappear in a diseased individual by administering a homeopathic dilution of the substance which has been able to cause the same symptoms in a 20 healthy subject. - The principle of infinitesimality states the fol lowing: For a substance to be capable of curing in a diseased subject the symptoms which it produces in a healthy 25 subject, it must be prescribed in a small dose. In the prior art, the use of homeopathic remedies is based on the presence of a small dose of active product in the homeopathic dilution, and this use consists in stimu lating the organism's reactions by means of these small 30 doses. - Thus, in the prior art, in order to treat a patient who suffers from cystic fibrosis and coughing, those skilled in the art have at their disposal more than 30 remedies used for treating coughs, each being defined 35 by its proving, i.e. by the symptom complex of coughing -3 which the substance contained in the remedy has been able to determine in a previously healthy subject. - Thus, an autoimmune disease is treated in the prior art by using organotherapy: 05 - Organotherapvy consists in administering homeopathic dilutions of the organ which is the seat of the auto immune disease. According to the principle of infini tesimality, the small doses of organs contained in the homeopathic dilutions bind to the circulating autoanti 10 bodies. The complex formed is eliminated via the natural routes and the abnormal antibodies are thus diverted from their target. (All the quotations are extracted from Galenica Volume 16: M~dicaments Homdopathiques (Homeopathic 15 Drugs)). The invention relates to a second therapeutic use of homeopathic remedies which are no longer used according to the law of similars, the principle of similars, the principle of infinitesimality, and pro 20 vings, in order to cause a series of symptoms to dis appear in a diseased subject by using an infinitesimal dose of the same substance which, in a ponderal dose, has been able to cause the same series of symptoms in the healthy subject, but which are used on the one hand 25 to cause the elimination of chemical substances from the cell and from the organism, and on the other hand, by causing this elimination, to restore normal function to perturbed pericellular transport systems with respect to these chemical substances. 30 The invention makes use of a known property of homeopathic dilutions which has only been studied experimentally in vitro: since the experiments of Lise WURMSER (subsequently repeated by numerous authors), it has been found that a homeopathic dilution of a product 35 causes the elimination from the organism of a ponderal -4 dose of the product from which it was prepared, the eliminated product being stored inside the cells; the term product denoting any chemical substance here. Lise WURMSER and her coworkers injected laboratory 05 animals with arsenic and then injected these guinea pigs with a homeopathic dilution of arsenic. Lise WURMSER showed that, under the influence of the homeo pathic dilutions of arsenic, an increased elimination of the injected arsenic was found in the urine and 10 stool of the guinea-pigs. These experiments have sub sequently been repeated by numerous authors, especially with lead, antimony and again with arsenic. Original clinical observations made by the author of the present invention have shown her that 15 this experimental property of elimination can also be utilized in clinical prescriptions of homeopathic dilu tions. The invention consists in applying an original and novel conclusion to the work of Lise WURMSER, this conclusion being as follows: that the homeopathic dilu 20 tion of arsenic exerted on the arsenic stored inside the cells a sufficiently strong electromagnetic attrac tion to cause it to leave the cells, and that the result of this attraction was to obtain an electromag netically neutral compound which was then eliminated 25 via the natural routes, namely the urine and stool. According to the invention, this property of reverse electromagnetic attraction is formed during dynamiza tion when the homeopathic remedies are manufactured, and the electromagnetic attraction is the stronger the 30 higher the dilution and, consequently, the greater the number of dynamizations. According to the invention, the higher the homeopathic dilution and hence the greater the number of concomitant dynamizations, the greater is the power of elimination: thus, according to 35 the invention, a 30CH possesses a greater power of -5 elimination than a 15CH, which in turn has a greater power of elimination than a 5CH. In the prior art, the use of homeopathic reme dies according to the law of similars is based on the 05 presence of a small dose of active product in the dilu tions, and it is the low dilutions which contain the greatest amount of active product and which are conse quently the most effective. The direct applications of this second thera 10 peutic use of homeopathic remedies and this property of elimination of chemical substances from the cell and from the organism involve intoxications and viral diseases. - For intoxications, the object of the invention is to 15 use the poison in homeopathic dilution in order to cause its elimination from the cells and from the organism. - For viral diseases due to the intracellular presence of a pathogenic virus or pathogenic viral fragment, as 20 is the case of cancers, the object of the invention is to use the virus or viral fragment in homeopathic dilu tion so as to cause the elimination of this virus or this viral fragment from the cells and from the orga nism. 25 For both these indications, namely intoxica tions and viral diseases, the dilutions used are pre ferably high so as to cause the greatest possible elimination. - Another field of the invention is the estab 30 lishment, by original clinical observations, that this elimination of intracellular components from the cell and from the organism can have a durable influence on the function of the pericellular transport systems. The invention therefore consists in utilizing this pro 35 perty of elimination of intracellular chemical sub- - 6 stances from the cell and from the organism under the influence of their homeopathic dilutions in order to restore normal function to the perturbed pericellular transport systems. 05 - In the prior art, diseases due to functional anomalies of the pericellular transport systems are qualified as genetic. The only functional anomalies of these transport systems which are known in the prior art are the functional anomalies of the ion channels, 10 and the only known ion channels are the sodium, potas sium, calcium and chlorine channels. The invention consists of the deduction, from original clinical observations pertaining to the administration of homeo pathic remedies, that the passage of chemical sub 15 stances from the outside to the inside of the cell, and vice-versa, is due to multiple pericellular transport systems and that these function according to the laws of osmosis, causing the chemical substances to pass from the more concentrated medium to the less concen 20 trated medium. According to the present invention, the ion channels are a particular case of these systems for transporting chemical substances. Hitherto, in the prior art, a ponderal dose (i.e. non-homeopathic dose) of chemical substances, 25 most frequently protein substances, was used to modify the function of the ion channels and the transport of ions from the outside to the inside of the cell, which substances, by binding to certain receptor sites (for example of the ion channels), modify the passage of 30 ions into and out of the cell. Examples which may be mentioned are: - diuretics: . Lasilix (furosemide), which inhibits the resorption of chlorine and sodium at Henle's loop in 35 the kidney.

-7 Adactone (spironolactone), which is located on different extrarenal receptors and on the distal convoluted tubule in the aldosterone action sites at the sodium-potassium exchange points, and which behaves 05 like an aldosterone antagonist by blocking its receptor sites. - calcium inhibitors, which bind to protein receptor sites in the smooth muscle and cardiac muscle and pre vent calcium from entering the cell by way of the 10 calcium channels. These calcium inhibitors block the slow calcium channels. To act on the ion channels, research is moving towards genetic manipulations: this is the case of cystic fibrosis. It is also the case of viral diseases 15 caused by the intracellular penetration of a virus or viral fragment, where genetic manipulations are being attempted. When the transport systems involve substances other than ions, there are no techniques in the prior 20 art. It is mentioned, however, that in the case of intracellular overloading with metals, chelating agents are commonly used in the prior art to cause the elimi nation of these metals from the cells and from the organism. 25 Conditions of intracellular ion deficit or excess are known in the prior art: these conditions are qualified as genetic diseases. Their origin is attri buted to anomalies situated on the chromosomes. Only for the case of cystic fibrosis does the prior art 30 assert that this genetic disease is due to a dysfunc tion of the pericellular ion channels, namely the sodium and chlorine channels. A further object of the invention is to assert that all diseases caused by the intracellular deficit 35 or excess of a chemical substance, and qualified in the prior art as genetic, are due to dysfunctions of pericellular transport systems with respect to the chemical substance which is in excess or deficit inside the cells. 05 The invention, which is based on these novel and original theories, consists in utilizing the pro perty of elimination of chemical substances from the cell and from the organism under the influence of their homeopathic dilution in order to restore normal func 10 tion to the perturbed pericellular transport systems with respect to these chemical substances. According to the invention, the ion channels and pericellular transport systems function along concentration gradi ents which cause the ions and other substances to pass 15 from the more concentrated medium to the less concen trated medium. According to the laws of osmosis, water follows the particles and it is the medium containing the larger number of molecules which becomes the less concentrated medium, so the transport systems become 20 blocked in the direction of entry into the cell if the cell already contains an excess of the chemical sub stance in question, or in the direction of exit from the cell if the cell already contains a deficit of the chemical substance in question. 25 These transport systems behave like a multitude of doors operating in only one direction, cf. the entrance doors of a supermarket, which allow entry or exit. These doors which allow the chemical substance in question to pass are blocked either in the direction 30 of entry into the cell when there is an intracellular excess of this chemical substance, or in the direction of exit from the cell when there is an intracellular deficit of this chemical substance. According to the invention, in the case of 35 diseases caused by intracellular retention, for example -9 of minerals, water passes into the cells, where the minerals are already present in large amounts, and reduces the concentration inside the cell, where there is the greatest amount of minerals. (Minerals are 05 taken as a non-limiting example, but it is possible to have intracellular retention of other products of various chemical types.) The minerals therefore have an indefinite tendency to accumulate inside the cell, where they are already in excess. The property of eli 10 mination of intracellular components from the cell and from the organism under the influence of their homeo pathic dilution is immediately applicable to this type of complaint. The homeopathic dilution of the com ponent in excess causes the component (or whatever the 15 chemical substance may be) which is in excess to leave the cells, reducing the intracellular overloading. However, there is another mechanism to explain an action on the pericellular transport systems: the administration of the homeopathic dilution of the pro 20 duct which is in excess in the cell also causes water to be drawn around the eliminated molecules, since water follows the minerals and other products and leaves the cell. The extracellular medium becomes punctually less concentrated than the intracellular 25 medium. The pericellular transport systems corres ponding to this point, which are regulated along a concentration gradient, i.e. some of the entrance doors swing to expel from the cell the product which could only enter it. The consequences of these punctual and 30 repeated eliminations of a few molecules are a long term restoration of normal function to the transport systems under the influence of the repeated adminis tration of the homeopathic remedy in question over weeks, months and years. The dilutions used according 35 to the invention are preferably high, for example 15CH - 10 to 30CH, because, according to the invention, these high dilutions cause a more vigorous elimination than low dilutions. Their action extends over several con secutive days, so their frequency of administration is 05 1 or 2 times a week. According to the invention, in diseases caused by an intracellular deficit of any product, for example a mineral, the deficient intracellular medium impove rished in molecules of ions or of another product 10 contains only a little water, since the water has flowed towards the extracellular sector rich in mineral ions (or another product). The interior of the cell has become more concentrated than the exterior of the cell, and the transport systems, which are regulated 15 along a concentration gradient and transport from the more concentrated medium to the less concentrated medium, are blocked in the exit direction. According to the invention, the administration in this case of a homeopathic dilution of the product which is 20 in intracellular deficit causes: - either the elimination from the cell of the few remaining molecules of the product or mineral, which causes the intracellular concentration to drop punctually to zero and thereby incites a transporter to 25 swing in the direction of entry in order to cause the deficient ion or product to enter the cell at the point where the concentration was zero; - or neutralizes molecules of the product or mineral in the extracellular sector and eliminates them 30 to leave the water molecules which alone surrounded them. According to the laws of osmosis, to re-estab lish an equal water concentration on either side of the cell membrane, these water molecules enter the cell and it is the cell which will punctually become the less 35 concentrated medium. The doors of the corresponding - 11 transport system swing and position themselves in the direction of entry into the cell. According to the invention, repeated adminis trations of a homeopathic dilution of the mineralor 05 product which is in intracellular deficit have the long-term consequence of swinging a large number of molecular transport systems in the direction of entry into the cells and restoring normal function to these cells by restoring normal function to the pericellular 10 transport systems. The dilutions used according to the invention are preferably low, non-limiting examples being 4CH, 5CH or 7CH, because these dilutions cause a less vigorous elimination than high dilutions. Their effect is short-lived and they must be administered 15 daily according to the invention. According to the invention, the restoration of normal function to the transport systems cures meta bolic diseases and anomalies which are secondary to these dysfunctions but in which the relationship with 20 the transport systems and the intracellular deficits or excesses can be obvious and direct or can be very indirect and not at all obvious. According to the invention, the posology of the homeopathic dilution is as follows: the administration 25 of the homeopathic dilution of the product in question must be regular and can last for a long time, often for several years. The frequency of the administrations and the degree of dilution of the compounds according to the invention vary from case to case and have to be 30 determined by the therapeutist. The general formula of the compounds is RxCH. By way of indicative and non-limiting examples, there follows a list of a number of chemical substances which R can be according to the invention: 35 NaCl (sea salt or Natrium Muriaticum) - 12 Reduced iron (Ferrum Metallicum) Black antimony sulfide (Antimonium Crudum) Gold (Aurum Metallicum) Potassium 05 Dipotassium phosphate or Kalium Phosphoricum Aluminum (Aluminium Metallicum) Dimagnesium phosphate (Magnesia Phosphorica) Tricalcium phosphate (Calcarea Phosphorica) Copper (Cuprum Metallicum) 10 Oyster limestone (Calcarea Carbonica) Oxalic acid Calcium oxalate (Calcarea Oxalica) Melanin (Melaninum) Cuttlefish ink (Sepia) 15 Viruses and viral particles of: HIV virus Virus of viral hepatitis type A, B, C etc. Coxsackie virus Epstein-Barr virus 20 Leukemia virus Other carcinogenic viruses. These compounds RxCH are presented in the form of granules or globules or in the other forms (ampoules, suppositories etc.) commonly used in homeopathy. The 25 administrations can be perlingual, per os, IM, IV, in the form of an ampoule or suppository or in any other possible medicinal form. To cause the elimination of a particle, the invention recommends the use of x = 30, i.e. R30CH, by 30 way of indication and without implying a limitation. To restore normal function to pericellular transport systems with respect to an intracellular deficit, according to the invention, it is recommended to use x = 5CH once a day in the form of granules at a 35 rate of 3 to 5 granules a day, by way of indication and - 13 without implying a limitation. To restore normal function to pericellular transport systems with respect to an intracellular excess, it is recommended according to the invention to 05 use x = 15CH in the form of a once weekly dose, by way of indication and without implying a limitation: R15CH. - In the case of viral diseases, for the com pound RxCH in which R is prepared on the basis of viral particles, 2 mechanisms of action are to be envisaged: 10 - In a number of cases, the compound RxCH causes the elimination from the cell and from the organism of the viral particle from which it is prepared. - In a number of other cases, the compound RxCH acts on pericellular transport systems with respect to the 15 viral particle by inhibiting its penetration into the cell and by allowing the elimination of the viral par ticle from the cell. In fact, in the case of some viruses, such as the HIV virus, the existence of peri cellular receptors has been demonstrated which allow 20 the virus to enter the cell and constitute a true peri cellular transport system. - In the case of intoxications where when R in the compound RxCH is a poison (or a fraction of the poison), the same 2 mechanisms of action of the com 25 pound RxCH are to be envisaged. - In some cases, simple elimination of the poison from the cell and from the organism. - In other cases, elimination of the poison from the cell by acting on pericellular transport systems. 30 - In the case of metabolic diseases, according to the invention, the restoration of normal function to the pericellular transport systems cures metabolic anomalies which are secondary to these dysfunctions, where the relationship with the intracellular deficits 35 or excesses can be obvious and direct or very indirect - 14 and not at all obvious. - When it is obvious and direct, the diseases are those which are caused by an intracellular excess or deficit of a chemical substance and in which the pathological 05 manifestations are the direct consequence of the intra cellular accumulation or intracellular deficit of this chemical substance: . For example cystic fibrosis, which is a direct con sequence of an intracellular excess of NaCl, caused by 10 perturbation of the pericellular transport systems with respect to NaCl. . For example tetany, which is caused by an intracellu lar deficit of magnesium secondary to perturbation of the pericellular transport systems with respect to 15 magnesium, and in which the pathological symptoms of the disease are symptoms of magnesium deficiency. - When this relationship is very indirect and not at all obvious, the diseases are those which are caused by an intracellular excess or deficit of a chemical 20 substance and in which the consequence of this excess or deficit is the production, by the cell, of abnormal substances responsible for the observed pathological manifestations. These substances have a structure possessing anomalies which are due to the abnormal con 25 ditions in which the cell functions, and which give rise to complaints that no longer have any relationship with the causal anomaly of the transport systems: thus the cells start to produce antibodies of abnormal structure which are responsible for allergies or, in 30 the case of autoantibodies, responsible for autoimmune diseases. Thus, secondary to the anomalies of the transport systems, the cells start to produce all kinds of chemicals of abnormal structure or in abnormal amounts, which are responsible for a very wide variety 35 of complaints, such as arterial hypertension in the - 15 case of an overproduction of aldosterone, gout in the case of an overproduction of uric acid, and dyslipemia and atherosclerosis in the case of abnormally high cholesterol or triglyceride levels, this list not 05 implying a limitation. Examples of clinical observations show: - that the consequence of an intracellular deficit caused by an anomaly of the pericellular transport systems with respect to NaCl will be the production, by 10 the cells, of abnormal type IgE antibodies responsible for allergic rhinitis, and an overproduction of thyroid hormones, which is responsible for hyperthyroidism; - that the consequence of an anomaly of the pericellu lar transport systems with respect to black antimony 15 sulfide is the production, by the cells, of autoimmune antibodies or inflammatory metabolites responsible for chronic rheumatoid polyarthritis; - that the consequence of an intracellular deficit of gold caused by a breakdown of the pericellular trans 20 port systems with respect to gold can be the production of autoimmune antibodies by the cells. All these diseases caused by a dysfunction of the transport systems, according to the invention, are known in the prior art as genetic diseases, and ano 25 malies of certain genes which explain the observed pathological conditions have in fact been described. According to the invention, correction of the dysfunc tions of the pericellular transport systems by the use of the homeopathic compounds RxCH also corrects the 30 chromosomal anomalies governing the dysfunctions of the pericellular transport systems and interrupts the gene tic transmission of these diseases. In fact, according to the invention, correction of the dysfunction of the pericellular transport systems acts on the gene anoma 35 lies situated on the chromosomes, normalizing them as - 16 well. According to the invention, the functional anomalies of the pericellular transport systems may have other origins and other causes than hereditary transmission. 05 Examples of metabolic diseases often called genetic, to be treated with the compounds RxCH accor ding to the invention, are given below by way of indication and without implying a limitation: 10 A) Diseases caused by an intracellular excess: Example 1: Cystic fibrosis Cystic fibrosis is a so-called genetic disease charac 15 terized by an excess of sodium chloride in the secre tions and inside the cells. Some authors also report an excess of potassium. No treatment exists in the prior art. Researches are based on the hypothesis that it would be possible to use a protein called CFRT, 20 which would prevent NaCl from entering the cells, or that it would be possible to use genetic manipulations. The object of the invention is to treat cystic fibrosis with a compound of the formula RxCH in which R, by way of indication and without implying a limitation, can be 25 NaCl or any other salt capable of acting on the ion overload in question and the defective ion channel, such as potassium chloride, sodium iodide or iodine chloride, or compound salts of sodium, chlorine, potas sium and iodine which comprise all or some of these 30 elements, and in which x can preferably be equal to 15 or 30. Example 2: Pigmentary retinopathy Pigmentary retinopathy is an incurable so-called 35 genetic disease which is due to an accumulation of - 17 melanotic or other pigments in the cells of the retina and which culminates in blindness. The invention consists in treating this complaint with the compound RxCH in which R, by way of indication, can be melanin 05 or Sepia, a well-known homeopathic active product which is melanin mixed with impurities, or another pigment, and in which x is preferably equal to 15 or 30. Example 3: Oxalosis 10 This is a so-called genetic disease in which there is an intracellular accumulation of oxalic acid or calcium oxalate. This complaint is observed in children and culminates in death due to renal insufficiency. The invention consists in treating oxalosis with the com 15 pound RxCH in which R can preferably be oxalic acid or calcium oxalate and in which x can preferably be equal to 5, 15 or 30. Example 4: Hyperkalemic periodic paralysis 20 This is a so-called genetic disease which consists of attacks of paralysis caused by an intracellular as well as extracellular excess of potassium. Its treatment in the prior art consists in administering diuretics which inhibit carbonate dehydratase. Geneticists locate the 25 genetic anomaly on chromosome 17. The object of the invention is to treat this disease with the compound RxCH in which R is preferably potassium or a potassium salt, for example dipotassium phosphate (or Kalium Phosphoricum, a known homeopathic active product) and 30 in which x can preferably be equal to 15 to 30. Example 5: Hemochromatosis Hemochromatosis is a so-called genetic disease due to the intracellular accumulation of iron. Its treatment 35 in the prior art consists of blood lettings and the - 18 administration of Desferal, a chelating agent for iron. The object of the present invention is to treat hemo chromatosis with the compound RxCH in which R is pre ferably iron and in which x is preferably equal to 15 05 or 30. Example 6: Wilson's disease Wilson's disease is a disease due to the intracellular accumulation of copper. Its treatment in the prior art 10 consists in administering penicillamine, a chelating agent for copper. The object of the present invention is to treat Wilson's disease with the compound RxCH in which R can preferably be copper and in which x can preferably be equal to 5, 15 or 30. 15 Example 7: Alzheimer's disease This is a disease in which an excess of aluminum has been found. The invention relates to the use of the compound RxCH to treat Alzheimer's disease. R can pre 20 ferably be aluminum or 1 other aluminum salt or deri vative and x can preferably be equal to 5, 15 or 30. B) Diseases caused by an intracellular deficit: 25 Example 8: Tetany This is a disease which consists of muscular spasms caused by an intracellular deficit of calcium or magnesium. In the case of an intracellular deficit of magnesium, this disease is said to be genetic and its 30 treatment in the prior art consists in administering magnesium. The invention in this case relates to the use of the compound RxCH in which R is dimagnesium phosphate (Magnesia Phosphorica) and in which x is pre ferably equal to 4CH, 6DH, 5CH or 7CH to treat the so 35 called genetic form of tetany.

- 19 In other cases of tetany, R can preferably be tri calcium phosphate, Calcarea Phosphorica, or other salts or chemical substances. 05 Example 9: Vitamin-resistant rickets This is a particular form of rickets in children. The present invention consists in treating this complaint with the compound RxCH in which R can preferably be: - calcium or mineral salts derived from calcium 10 - oyster limestone or Calcarea Carbonica - tricalcium phosphate. Example 10: Hypokalemic periodic paralysis This is a so-called genetic disease which, like Example 15 4, consists of attacks of paralysis, except that the paralysis here is caused by an intracellular as well as extracellular deficit of potassium; the object of the invention is to treat it with the compound RxCH in which R, by way of indication, can preferably be 20 potassium or 1 potassium salt, for example dipotassium phosphate or Kalium Phosphoricum, a well-known homeo pathic active product, and in which x can preferably be equal to 5. 25 Example 11: Anemia caused by an intracellular deficit of iron This is a little-known complaint which is characterized in that the red blood corpuscles are small and the hematocrit is low, and which manifests itself by symp 30 toms of anemia. The invention consists in treating this form of anemia with the compound RxCH in which R is preferably iron and or x is preferably equal to 5. 35 - 20 C) The group of diseases which are related that very secondarily to the transport system anomalies which caused them: 05 Example 12: Rheumatoid polyarthritis The clinical studies performed by the author of the present invention have shown that this autoimmune disease of previously indeterminate origin is due to an anomaly of the pericellular transport systems with 10 respect to black antimony sulfide, there being an intracellular deficit of black antimony sulfide. The object of the invention is to treat this complaint with the compound RxCH in which R is preferably black anti mony sulfide and in which x is preferably equal to 4, 5 15 or 7. The invention further relates to the treatment of other autoimmune complaints, not accompanied by polyarthritis, with the same compound RxCH in which R is preferably black antimony sulfide. The author of 20 the present invention has observed a case of anti platelet autoimmunization which falls in this category. Example 13: Systemic lupus erythematosus The invention relates to the treatment of this auto 25 immune complaint with the compound RxCH in which R is preferably gold and in which x is preferably equal to 4, 5 or 7. Example 14: Amyotrophic lateral sclerosis 30 The clinical studies performed by the author of the present invention have shown that this incurable disease may be an autoimmune disease caused by an anomaly of the pericellular transport systems with respect to phosphorus. 35 The object of the invention is therefore to treat this - 21 disease with the compound RxCH in which R can pre ferably be phosphorus or a salt derived from phosphorus and in which x can preferably be equal to 5, 15 or 30. Multiple sclerosis, according to the invention, is a 05 very similar disease which benefits from the same type of treatment with the same compound RxCH in which R can preferably be phosphorus or a salt derived from phos phorus. 10 Example 15: Hyperthyroidism The clinical studies performed by the author of the present invention have shown that this disease is due to a disorder of the pericellular transport systems with respect to NaCl, there being an intracellular 15 deficit of NaCl. It will be noted that cystic fibro sis, which involves an intracellular excess of NaCl, is a totally different entity. The object of the inven tion is to treat hyperthyroidism with the compound RxCH in which R is preferably NaCl in which x is preferably 20 equal to 6DH, 4CH, 5CH or 7CH. D) The group of viral diseases: Example 16: Viral diseases 25 The compound RxCH according to the invention has the property of expelling viral particles from the infected cells and then of causing their elimination in the form of an inactive compound via the natural routes. The inactive compound is due to the combination of a pon 30 deral dose of the viral particle leaving the cell and its homeopathic dilution. It may also be considered that the homeopathic dilution prepared on the basis of viral particles can act on pericellular transport systems with respect to these viral particles, preven 35 ting the intracellular penetration of these viral - 22 particles. - In the case of AIDS, the viral particles are held by the Institut Pasteur, which uses them for nucleic acid molecular hybridization techniques and for genetic 05 engineering techniques, which consists in producing viral proteins by means of microorganisms into which viral genes have been injected. These viral particles are also used for performing serum analyses or for experimental purposes to produce vaccines. 10 - In the case of the hepatitis B virus, the viral particles are also held by the Institut Pasteur. - The Institut Pasteur also holds viral particles of other viruses for performing serum analyses or for experimental purposes. 15 As regards viral complaints, the invention relates to a treatment with the compound RxCH in which x is pre ferably equal to 30 and in which R, by way of indica tion and without implying a limitation, can be: - 1 viral RNA or 1 viral DNA 20 - viral RNA or viral DNA fragments - 1 or more viral proteins - 1 or more viral protein fragments - 1 whole virus. The viral complaints to which the invention relates can 25 be any viral complaint; by way of indication and without implying a limitation, there may be mentioned AIDS, hepatitis A, B or C etc., viral cancers, slow or fast virus neurological diseases, and viral diseases of animal origin, such as feline retrovirus leukosis in 30 cats, bovine leukosis and lentivirus lymphosarcoma in dogs. In the case of animal diseases, the viral particles are normal components of certain vaccines or are held by pharmaceutical or experimental veterinary laboratories. 35 - 23 E) The group of miscellaneous diseases: Example 17: Miscellaneous diseases Finally, the following complaints may be mentioned as 05 other examples of metabolic diseases, without implying a limitation: Refsum's disease, or R can be phytanic acid, Charcot-Marie-Tooth and Ddjerine-Sottas disease, Huntington's chorea, where R can be zinc, Thevenard's disease, Friedrich's disease, Pierre Marie's hereditary 10 cerebellar ataxia, Strumpell Lorrain's periodic paraly sis, Roussy-Ldvy syndrome, dyslipidosis, idiopathic mental retardations in children, and autism. Some clinical observations of cases of patients treated 15 with compounds RxCH according to the invention are reported below. CASE No. 1 A 72-year-old female patient presenting with a very 20 matt complexion and slight trembling of the two upper limbs. A systematic examination for an episode of asthenia shows abnormally high serum iron at 173 microg/liter, i.e. 31 micromol, on 11-10, but not hemochromatosis. Ferrum Metallicum 15CH is prescribed 25 at a rate of one dose every Sunday for a period of one month starting on 17-10. - On 16-11, i.e. at the end of the treatment, the serum iron is assayed again. It has fallen to 103.41 microg, i.e. 18.50 micromol. The patient has suffered no 30 hemorrhaging and the very significant drop in the serum iron from * 31 micromol to 18.5 micromol * 173 microg/l to 103 microg/l is due to the administration of Ferrum Metallicum, 35 which has caused the elimination of the iron from the - 24 organism. The general condition is improved. The trembling is less pronounced. - A further assay of the serum iron is requested 2 05 months later at the end of January, i.e. 2k months after cessation of the one-month treatment with Ferrum Metallicum 15CH. The serum iron has risen but has not reached its original level. It is: . 25 micromol/l, i.e. 139.75 microg/l, 10 proving that the patient carries a metabolic anomaly which gives her a spontaneously high iron level, or that she absorbs iron abnormally, which is not the case since her diet excludes this possibility. On 31st January, Ferrum Metallicum 15CH is prescribed again at 15 a rate of one dose every Sunday for one month with no repeat assay at the end of the treatment. During this winter, an improvement in the general condition is noted, together with an absence of the bronchitis episode which usually occurred every winter and lasted 20 about one month. The following July, the serum iron is assayed again and is: . 26.80 micromol/l, i.e. 149.81 microg/l, in other words steady. This case illustrates the theories and experiments 25 pertaining to guinea-pigs, namely that the product whose homeopathic dilution has been administered is eliminated from the organism. This elimination invol ves a withdrawal of ions from the cells, the iron being stored intracellularly. Furthermore, the patient cited 30 here, who has a spontaneous tendency towards high serum iron, could well carry a minor and very attenuated heterozygous form of hemochromatosis, and this case would also concern the theories of the invention pertaining to this complaint. 35 - 25 CASE No. 2 A 44-year-old female patient presenting with hyper thyroidism due to multinodular thyroid hyperplasia, and morning allergic rhinitis. Mapping showed hypertrophy 05 of the right lobe with a cold nodule. The biological examinations performed after the first consultation showed hyperthyroidism with the following results: on 19-02 TSH: 0.02 T4f: 35 10 The normal levels are 0.2 to 4 for TSH and 10 to 25 for T4f. The TSH is abnormally low and the free T4 abnor mally high. The patient receives treatment with a synthetic thyroid inhibitor, namely Basdene on its own, starting on 22-02, at increasing doses of 1 tbl on the 15 1st day, 2 tbl on the 2nd day and then 3 tbl per day. On 3-03 TSH: 0.02 T4f: 36.8 Therefore, a few days after the start of the Basdene treatment, the hyperthyroidism has remained 20 identical and even become slightly worse. On 7-03, the patient is seen again by the consultant and, in place of Basdene, Neo-mercazole is prescribed at doses of 3 tbl 3 times a day: on 17-03 TSH: 0.02 25 T4f: 33.8 The thyroid hormone level after 10 days of Neo mercazole is still just as high, with no improvement. On 20-03, the patient is seen again and the following is added to the Neo-mercazole treatment for 30 the allergic rhinitis: NATRIUM MURIATICUM 6DH, 3 tbl/1 for 7 days, then NATRIUM MURIATICUM 4CH, 3 granules/1 for 15 days. On 13-04 T4f: 25.1 For the first time, the thyroid hormone level 35 has normalized again and the abundance of the allergic - 26 rhinitis has reduced by 3/4. In order to know whether it is the Natrium Muriaticum or the Neo-mercazole which has normalized the thyroid functions, the Neo-mercazole is suddenly 05 withdrawn, which, if it is the Neo-mercazole which has lowered the T4f, should have the effect of raising it immediately to 30, and the regular administration of Natrium Muriaticum 4CH is continued on 13-04. On 27-04: T4f = 26.9,, i.e. still normal, pro 10 ving that it is indeed the Natrium Muriaticum and not the Neo-mercazole which has cured the hyperthyroidism and normalized the level of T4f. The precise doses of Natrium Muriaticum which were in fact taken are: - Natrium Muriaticum 6DH: 3 tbl/day from 20-03 15 to 11-04, then Natrium Muriaticum 4CH: 3 granules/day from 11-04 to 28-04. On 28-04, the patient is seen again by the consultant and the prescribed dose of Natrium Muriaticum is further modified, being increased to Natrium Muriaticum 5CH: 3 granules a day. 20 The Neo-mercazole was of course never restarted. The effect of this change in doses of Natrium Muriaticum is to further lower the thyroid hormone: on 27-04 T4f: 26.9 on 10-06 T4f: 18.6 25 The following dose of Natrium Muriaticum 5CH is still continued from this time on: 3 granules a day. - On 1-08, the allergic rhinitis is found to have disappeared. - Meanwhile, on 10-07, the patient had an 30 operation on her multinodular hyperplastic goiter con taining cold nodules, which was suspected of neoplasia despite the numerous punctures which had never shown anything alarming. There was no cancer on the operated part. On 1-08, the result of this operation is a T4f 35 of 13.8, which is now near the lower limit of the norm - 27 (the norm being 10 to 25). A tendency towards hypo thyroidism might be feared. This is not so at all: - on 9-10 TSH: 2.14 T4f: 16.7 05 The thyroid functions are therefore normal. The allergic rhinitis has disappeared, the Natrium Muriaticum 5CH still being continued at a rate of 3 granules a day. In conclusion, this example illus trates the fact that hyperthyroidism is indeed a 10 disease caused by an intracellular deficit of NaCl and that the prescription of NaCl 5CH, by acting on the restoration of normal function to the transport sys tems, virtually immediately normalizes the thyroid hormone metabolisms which were perturbed. 15 Another perturbed metabolism normalizes again: this is the production of abnormal type IgE antibodies respon sible for the allergic rhinitis, which ceases com pletely after a few months of treatment and which had begun to decrease and improve as soon as the first 20 doses of homeopathic remedy had been administered. CASE No. 3 A 7-year-old female child suffering from juvenile chronic polyarthritis, an autoimmune disease qualified 25 as genetic. After examination of the clinical case, it appears that the homeopathic symptoms correspond to an intracellular deficit of black antimony sulfide. At the first con sultation, the patient presents with polyarticular 30 symptoms localized especially in the elbows and knees, requiring a daily administration of Naprosyn and phy siotherapy sessions. The Naprosyn is taken at a dose of 1 tbl of 250 mg a day and is not sufficient to sup press the symptoms, since the disease worsens. It is 35 this which motivates consultation. Antimonium Crudum - 28 5CH, 3 to 5 granules once a day, is added to the Napro syn as from 27-12. The articular condition improves so substantially after this date that the doses of Napro syn, which would have had to be increased, are reduced; 05 at the beginning of the following April, the Naprosyn is completely withdrawn and a small amount of Voltaren is taken from time to time. The following July, the right arm, which was deformed, has completely straigh tened again. The elbow joint has normalized again. 10 The symptoms of polyarthritis have disappeared. Of course, the child took 3 to 5 granules of Antimonium Crudum 5CH every day throughout this time. As from July, the antiinflammatories are withdrawn and the treatment with Antimonium Crudum 5CH is still con 15 tinued. It will be maintained for several years. Conclusion This case illustrates the fact that it has been pos sible to cure a so-called genetic autoimmune disease by restoring normal function to the pericellular transport 20 systems. Chronic rheumatoid polyarthritis here proves to be a disease caused by an intracellular deficit of black antimony sulfide. In conclusion, this case and the previous case verify 25 the theory of the invention, which asserts that cor rection of the functional anomalies of the pericellular transport systems secondarily normalizes the perturbed metabolisms. 30 CASE No. 4 A 3k-year-old Alsatian-type dog suffering from canine autoimmune polyarthritis, a disease which would corres pond to systemic lupus erythematosus in human patho logy. The symptoms of this complaint are complete 35 seizure of the hindquarters and a fever of 4 0 ' or even - 29 41'. The conventional medical treatment starts on 8th July 1986 and consists in injecting corticoids at a rate of: Solu-Medrol 20 mg morning and evening, IM, under a 05 blanket of antibiotics maintained for about ten days. The corticoids are then gradually reduced. The Solu Medrol is replaced with Cortancyl 5 mg: 2 tbl a day. The homeopathic symptoms corresponded to an intracellu lar deficit of gold and to the prescription of Aurum 10 Metallicum. In August of the same year, a homeopathic remedy is added to the Cortancyl. However, the wrong homeopathic remedy is given: instead of Aurum Metalli cum, the dog is given Mercurius Solubilis: 3 to 5 granules a day. As from the beginning of September, 15 trusting in a cure, the Cortancyl is gradually reduced. The disease immediately recurs and it is necessary to resume the treatment with Solu-Medrol 20 mg morning and evening, IM, for about ten days, again followed by Cortancyl 5 mg: 2 tbl/day, the Mercurius Solubilis of 20 course being withdrawn. On 18th March of the following year, when it has been possible to reduce the doses of Cortancyl 5 mg to 1 tbl/day, Aurum Metallicum 5CH, 3 to 5 granules a day, which is now the right prescription, is added this 25 time. Two months later, it has been possible success fully to reduce the Cortancyl, which is now taken at a dose of only 1 tbl of 5 mg once a week, every Monday. For a few days in April, the administration of Aurum Metallicum 5CH is forgotten, which, one morning, causes 30 aphonia (complete loss of voice and bark) and by slight incipient stiffness of the hindquarters. The treatment with Aurum Metallicum 5CH is immediately resumed at a rate of 3 granules several times a day (3 times), accompanied by Ledum Palustre 7CH: 3 granules twice a 35 day, for 3 days. The treatment is subsequently con- - 30 tinued at the following doses: Aurum Metallicum 5CH: 5 granules a day Aurum Metallicum 7CH: 3 granules a day The last tablet of Cortancyl 5 mg was given on 05 28-09-87 and the corticoids were then definitively withdrawn. The homeopathic treatment was continued at the above-indicated doses until August 1989, when it was definitively withdrawn. No relapse ever occurred. Conclusion 10 This case illustrates and confirms the theories of the invention and shows that this form of canine autoimmune polyarthritis is due to an intracellular deficit of gold and that the corresponding human disease, systemic lupus erythematosus, is probably also due to an intra 15 cellular deficit of gold. It also shows that the invention in the long term restores normal function to the pericellular transport systems without the possibility of a relapse, and that restoring this normal function to the transport systems 20 suppresses the metabolic anomalies of the cells, i.e. in this case the production of abnormal antibodies. 25 30 35

Claims

1. Application of homeopathic compounds of the general formula RxCH to the elimination of an intra cellular chemical substance R from the cell and from the organism in order to obtain drugs intended for causing this elimination. In the general formula RxCH, xCH is one of the possible decimal or centesimal hahnemannian homeopathic dilutions or korsakowian homeopathic dilutions or one of the possible homeo pathic dilutions of another system, these dilutions being accompanied by concomitant dynamizations.

2. Application of homeopathic compounds of the general formula RxCH to the elimination of an intra cellular chemical substance R from the cell, when this elimination causes the restoration of normal function to the perturbed pericellular transport systems, in order to obtain drugs which, by causing this elimina tion from the cell, are intended for restoring normal function to the perturbed pericellular transport systems. If the intracellular chemical substance R is a mineral, it is a question of restoring normal func tion to an ion channel whose function has been pertur bed. By restoring normal function to the pericellular transport systems, these drugs are intended for treat ing diseases caused by an intracellular accumulation or intracellular deficit of a simple or complex chemical substance, or diseases which are indirect consequences of these intracellular accumulations or these intra cellular deficits.

3. Application of homeopathic compounds of the general formula RxCH to the preparation of drugs according to claims 1 and 2, when the intracellular chemical substance R is a poison or part of a poison, which drugs are characterized in that they are intended - 32 f or treating intoxication by causing the elimination of the poison from the organism.

4. Application of homeopathic compounds of the general formula RxCH to the preparation of drugs according to claims 1 and 2, when the intracellular chemical substance R is a simple or complex viral particle such as a whole virus, viral DNA or RNA, a viral DNA or RNA fragment, a viral protein or protein fragment or any other viral component, which drugs are intended for treating viral diseases by causing the elimination of the viral particles from the organism. Examples of the viral diseases in question are AIDS, viral cancers and leukoses, slow virus neurological diseases, viral hepatites, feline leukosis in cats and any other human or animal viral disease.

5. Application of homeopathic compounds of the general formula RxCH to the preparation of drugs according to claims 1 and 2 which are intended for treating diseases caused by a metabolic error, when the radical R is the chemical substance responsible for the metabolic anomaly.

6. Application of homeopathic compounds of the general formula RxCH to the preparation of drugs according to claims 1, 2 and 5 which are intended for treating metabolic diseases, when the metabolic error consists of an intracellular accumulation or intra cellular deficit of a chemical substance of simple or complex formula, caused by a functional anomaly of the pericellular transport systems with respect to the corresponding chemical substance. If this chemical substance is a mineral salt, the functional anomaly is that of the corresponding ion channel.

7. Application of homeopathic compounds of the general formula RxCH to the preparation of drugs according to claims 1, 2, 5 and 6 which are intended - 33 for treating diseases caused by a metabolic error, when the metabolic errors consist of the production of abnormal metabolites and very especially the production of abnormal antibodies and autoantibodies, which drugs are consequently characterized in the latter case in that they are intended for the treatment of all auto immune diseases.

8. Application of homeopathic compounds of the general formula RxCH to the preparation of drugs according to claims 1, 2, 5, 6 and 7 which are intended for the treatment of metabolic diseases, when the metabolic errors are coded for by a chromosomal frag ment or by a very specific chromosome, this being the definition of a genetic disease, which drugs are consequently intended for the treatment of genetic diseases.

9. Drugs, characterized in that they contain a homeopathic compound RxCH and one or more inert exci pients, excipients intended for increasing the activity of the compound RxCH or no excipient at all, and in that they are presented in any physiologically accep table pharmaceutical form, especially in the form of granules, globules, tablets, gelatin capsules, solu tions to be taken orally or injected, and supposi tories.